Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

References

• Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2011;115:453–474.
   Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD, . The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268–274.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–1812.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773.
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, . Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010;29:6409–6417.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, . IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474–478.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17–30.
   PubMed Web of Science ®Google Scholar
• Abbas S, Lugthart S, Kavelaars FG, . Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010;116:2122–2126.
   PubMed Web of Science ®Google Scholar
• Boissel N, Nibourel O, Renneville A, . Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010;28:3717–3723.
   PubMed Web of Science ®Google Scholar
• Chotirat S, Thongnoppakhun W, Promsuwicha O, . Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol 2012;5:5.
   PubMed Web of Science ®Google Scholar
• Chou WC, Hou HA, Chen CY, . Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749–2754.
   PubMed Web of Science ®Google Scholar
• Chou WC, Lei WC, Ko BS, . The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246–253.
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Hills RK, . The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010;116:2779–2782.
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Zhao L, . The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409–412.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, . IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–2355.
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, . Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–1066.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636–3643.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Haferlach C, Ulke M, . IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010;116:5486–5496.
   Google Scholar
• Thol F, Damm F, Wagner K, . Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614–616.
   PubMed Web of Science ®Google Scholar
• Thol F, Weissinger EM, Krauter J, . IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668–1674.
   PubMed Web of Science ®Google Scholar
• Wagner K, Damm F, Gohring G, . Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356–2364.
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden VH, . Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474–2486.
   PubMed Web of Science ®Google Scholar
• Chou WC, Huang YN, Huang CF, . A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. Blood 2010;116:495–496.
   PubMed Web of Science ®Google Scholar
• Lin J, Yao DM, Qian J, . IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519–525.
   PubMed Web of Science ®Google Scholar
• Nomdedeu J, Hoyos M, Carricondo M, . Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leuk Res 2012.
   Web of Science ®Google Scholar
• Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010;86: 631–637.
   PubMed Web of Science ®Google Scholar
• Steinbach D, Sell W, Voigt A, . BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002;16:1443–1447.
   PubMed Web of Science ®Google Scholar
• Ho MM, Hogge DE, Ling V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 2008;36:433–442.
   PubMed Web of Science ®Google Scholar
• To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 2006;26:8572–8585.
   PubMed Web of Science ®Google Scholar
• To KK, Polgar O, Huff LM, . Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 2008;6:151–164.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y, . DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13–27.
   PubMed Web of Science ®Google Scholar
• Deneberg S, Guardiola P, Lennartsson A, . Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011;118:5573–5582.
   Google Scholar
• Zou Y, Zeng Y, Zhang DF, . IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 2010;402:378–383.
   PubMed Web of Science ®Google Scholar
• Zhou KG, Jiang LJ, Shang Z, . Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leuk Lymphoma 2012 Jun 18. [Epub ahead of print]
   Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010;102:932–941.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Capper D, Meyer J, . IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica 2010;95:1797–1798.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–744.
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339–344.
   PubMed Web of Science ®Google Scholar
• Jin G, Reitman ZJ, Spasojevic I, . 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011;6:e16812.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Abdel-Wahab O, . IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302–1309.
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369–370.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T, Finke C, . LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24:1713–1718.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Capper D, Luft T, . Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk Res 2010;34:1091–1093.
   PubMed Web of Science ®Google Scholar
• Rocquain J, Carbuccia N, Trouplin V, . Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10:401.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, . Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094–1096.
   PubMed Web of Science ®Google Scholar
• Ho PA, Alonzo TA, Kopecky KJ, . Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010;24:909–913.
   PubMed Web of Science ®Google Scholar